Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Open Access
- 1 April 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 6 (4), 219-228
- https://doi.org/10.1038/nrclinonc.2009.4
Abstract
Despite their inherent selectivity, targeted therapies such as tyrosine kinase inhibitors (TKIs) can cause unusual adverse effects. Sunitinib and sorafenib are multitargeted TKIs that have been demonstrated to induce hypothyroidism and thyroid dysfunction. Retrospective studies indicate that sunitinib can induce hypothyroidism in 53-85% of patients, and in prospective studies this complication has been reported in 36-71% of patients. Sorafenib has been reported to be responsible for hypothyroidism in 18% of patients with metastatic renal-cell carcinoma. Furthermore, imatinib and sunitinib seem to increase the requirement of levothyroxine in hypothyroid patients. The management of thyroid dysfunction and possible related symptoms, such as fatigue, represents a challenge to oncologists. We propose a diagnostic and therapeutic algorithm for the management of TKI-related hypothyroidism. Prospective trials are needed to define the incidence of overt and subclinical hypothyroidism and thyroid dysfunction during therapy with sunitinib, sorafenib and potentially other TKIs. The safety and efficacy, and optimal dosing and timing of starting replacement therapy in patients affected by TKI-related hypothyroidism need accurate appraisal and should be evaluated prospectively in appropriately designed trialsKeywords
This publication has 60 references indexed in Scilit:
- Transient Thyroiditis after Treatment with Lenalidomide in a Patient with Metastatic Renal Cell CarcinomaThyroid®, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI Journal of the National Cancer Institute, 2007
- Mechanisms of cutaneous toxicities to EGFR inhibitorsNature Reviews Cancer, 2006
- Rifampin-Induced Hypothyroidism in Patients with Hashimoto's ThyroiditisNew England Journal of Medicine, 2005
- Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic miceOncogene, 1999
- Drugs and Thyroid FunctionNew England Journal of Medicine, 1995
- Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin-2 AloneJournal of Immunotherapy, 1995
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsNew England Journal of Medicine, 1988
- Cyclical combination chemotherapy and thyroid function in patients with advanced hodgkin's diseaseMedical and Pediatric Oncology, 1981